Cargando…
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
BACKGROUND: PD-1 blocking agents, such as nivolumab, have demonstrated clear anti-tumor effects and clinical benefits in a subset of patients with advanced malignancies. Nonetheless, more efforts are needed to identify reliable biomarkers for outcome, to correctly select patients who will benefit fr...
Autores principales: | Capone, Mariaelena, Fratangelo, Federica, Giannarelli, Diana, Sorrentino, Claudia, Turiello, Roberta, Zanotta, Serena, Galati, Domenico, Madonna, Gabriele, Tuffanelli, Marilena, Scarpato, Luigi, Grimaldi, Antonio M., Esposito, Assunta, Azzaro, Rosa, Pinto, Antonio, Cavalcanti, Ernesta, Pinto, Aldo, Morello, Silvana, Ascierto, Paolo A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065327/ https://www.ncbi.nlm.nih.gov/pubmed/32160899 http://dx.doi.org/10.1186/s12967-020-02285-0 |
Ejemplares similares
-
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017) -
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022) -
Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023) -
CD73: A Promising Biomarker in Cancer Patients
por: Turiello, Roberta, et al.
Publicado: (2020) -
Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)